Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2006-01-31 Director's Dealing
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' under ASX listing rule 3.19A.2. It details the acquisition and disposal of securities by a director, including the exercise of options and changes in shareholdings. There is no financial performance data, management discussion, or report content. The document is a regulatory disclosure of insider transactions by a director, which fits the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive insider transaction report.
2006-01-31 English
Commitments Test Entity - Second Quarter Report 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities admitted on the basis of commitments.' It contains detailed financial data including consolidated cash flow statements for the quarter ended 31 December 2005 and year-to-date figures. The report includes operating, investing, and financing cash flows, payments to directors, reconciliation of cash, and compliance statements. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). Q2 2005
2006-01-30 English
Appendix 3B - Exercise of Employee Options 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically ordinary shares issued upon exercise of options under an employee option plan. It includes details such as the number of securities issued, issue price, purpose of the issue, and dates related to the securities. The document references ASX rules and is structured as a formal notification to the Australian Securities Exchange (ASX) about a capital change event. This type of document is a capital/financing update rather than a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on the issuance of shares and related securities information. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP).
2006-01-30 English
Release from voluntary escrow 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange regarding the release from voluntary escrow arrangements related to a 2005 public offering. It mentions the release date of shares and options from escrow and references Listing Rule 3.10A. The document is short (1102 characters) and serves as an announcement about share release conditions rather than a detailed financial report or other filings. It does not contain financial statements, management discussion, or detailed regulatory information. This fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2006-01-19 English
Signs first distributor for Aridol 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 18 January 2006 from Pharmaxis Ltd announcing the signing of a distribution agreement for its product Aridol. It discusses the marketing and regulatory approval process but does not contain financial statements, earnings data, or detailed financial analysis. It is a corporate announcement about a commercial agreement and product distribution, not a financial report or regulatory filing. The document length is 6265 characters, which is relatively short and consistent with a press release. There is no indication that this is an Annual Report, Earnings Release, or any other detailed financial or regulatory filing. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2006-01-17 English
US Filing of Annual Report on Form 20-F 134 pages ?Kb
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the United States SEC, which is an annual report for foreign private issuers. It is explicitly marked as an "ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934" for the fiscal year ended June 30, 2005. The content includes detailed financial data, operating and financial review, directors and management information, and other comprehensive disclosures typical of an annual report. The length of the document (15,000 characters) and the presence of substantive financial statements and analysis confirm it is the full report, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K equivalent for foreign issuers).
2005-12-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.